Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck HCV Combo Looks Even Better With Results In Patients Co-Infected With HIV

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Data released at the Conference on Retroviruses and Opportunistic Infections show therapeutic effect post-treatment, but Merck has not yet obtained sustained virologic response data in the Phase II study. The data on genotype 1a patients and hard-to-cure HCV subpopulations will inform the design and goals of the Phase III program.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel